IL-PROJECT44
30.6.2020 13:02:14 CEST | Business Wire | Press release
project44®, the global leader in advanced visibility for shippers and logistics service providers (LSP), today announced that it experienced a record-setting first half of 2020 with a 139% increase in bookings over the same period in 2019, with significant growth coming from global retailers, manufacturers, and distributors in North America and EMEA.
“project44’s momentum accelerates as we continue to unlock the strategic value of our platform with new innovative products, enterprise integrations and partnerships with tech leaders such as SAP and IBM, so together we can deliver greater business success for our customers,” said Jett McCandless, CEO and Founder of project44. “The last six months, when the economy was under immense pressure, have validated that real-time visibility has become an urgent must-have. As a result, project44 has emerged as both a category leader and the industry’s only global, multimodal visibility provider.”
“Our entire business philosophy is based on sustainability. By working with project44, we are looking to achieve even more supply chain sustainability and efficiency through seamless collaboration across our global logistics network,” said Anastasios Tasos Papadopoulos, Director Asset Management and Product Engineering Europe at IFCO Systems GmbH. "The real-time, accurate visibility data from across all modes and regions in a single platform helps us optimize our product flows and support our teams in managing of our shipments efficiently.”
In addition to exceptional business growth, project44 has achieved a number of important milestones, including:
Advanced Visibility Investment: In order to quickly meet the increasing demand for its products and services, project44 recently closed a round of funding which brings the total raised to over $50 million since Series C. The investment will enable the company to continue delivering on product innovation, rapid scalability of network breadth and depth, and global expansion.
Customer Traction : The company significantly increased its customer base in 2020, with key wins including Ferrero International, IFCO Systems GmbH, Lenovo, TIP Trailer Services, UniCarriers Americas Corporation, and more. As part of its rise to the dominant position, project44 is proud to deliver real-time transportation visibility to over 300 enterprise customers, which include the top 3 ranked companies on the Fortune 500 list, 2 of the 3 largest retailers in the world and 8 of the world’s top 10 freight brokerages, among others.
Geographic Expansion: project44’s business in EMEA has increased year-over-year by 303%. The customer community is now actively tracking over 21 million shipments in 120 countries, across North America, EMEA, LATAM, and APAC.
Product Innovation: project44 has quickly accelerated to become the only visibility company to provide one seamless global and multimodal experience . In May, the technology company added air freight and groupage visibility as well as expanded global ocean coverage to its platform. In addition to launching visibility into new modes and regions, project44 has continued to dominate the North American and European over the road markets with the announcement of multiple product advancements including an enhanced, predictive ETA model that calculates a shipment’s arrival status with 91% accuracy, built using data from over 3 million past shipments.
With Network Management Center™ (NMC), project44 continues to expand network onboarding capabilities to enable agility and operational efficiency through the entire transportation ecosystem, especially when fast time to value is critical. In addition to increasing the ways shippers and LSPs can connect to carriers and benefit from increased network stability , the application provides carriers with instant access to project44’s global customer base and, as a result, additional business opportunities.
Network Growth: As the only visibility provider to offer coverage across all modes of transportation, project44 delivers instant access to the most expansive and highest performing global network. This includes connections to more than 760 telematics/ ELD providers, representing 94% of the European market, and over 95% parcel coverage in North America and Europe. The company delivers 99.7% coverage of truckload and less-than-truckload carriers in North America and Europe with the majority consistently tracking over 90% compliance. It also provides ocean coverage for 85% of containers shipped globally and 100% coverage of the Class I and Class II railroads in North America. Earlier this year project44 announced the industry’s first service level agreement (SLA) , which ensures 90% of a shipper’s contracted full truckload carriers in North America and Europe go live within 30 days of commencing implementation.
Industry Recognition: project44 was recognized by SAP as Cloud Integration Partner of the Year for enabling global brands to build more agile supply chains. The winner was chosen based on recommendations from the SAP field, customer feedback, and performance indicators. project44 has placed second, behind only Amazon, on FreightWaves’ 2020 Freight Tech 25 , a list of the most innovative companies across the freight industry.
“Every day thousands of companies trust DSV with their transport orders," said Simon H. Galsgaard, EVP at DSV, the world's fourth largest transport and logistics company. "Operational excellence and efficiency are critical to our business, and so is advanced real-time visibility. With project44, as our preferred visibility provider, we're achieving real-time visibility across the entire DSV fleet of own and subcontracted assets, for the benefit of our customers.”
Learn more about project44 or schedule a demo today.
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates, and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. project44 has placed second, behind only Amazon, on FreightWaves’ 2020 Freight Tech 25, a list of the most innovative companies across the freight industry, and received the 2020 SAP® Pinnacle Award as the Cloud Partner Integration of the Year. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005151/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom